Prudential Financial Inc. Purchases Shares of 13,183 Zafgen Inc (NASDAQ:ZFGN)

Prudential Financial Inc. bought a new stake in shares of Zafgen Inc (NASDAQ:ZFGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,183 shares of the biopharmaceutical company’s stock, valued at approximately $65,000.

Several other large investors also recently added to or reduced their stakes in ZFGN. First Manhattan Co. acquired a new stake in Zafgen during the fourth quarter worth approximately $27,000. Meeder Asset Management Inc. boosted its holdings in Zafgen by 547.1% in the fourth quarter. Meeder Asset Management Inc. now owns 9,118 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 7,709 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Zafgen by 428.7% in the third quarter. Wells Fargo & Company MN now owns 14,783 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 11,987 shares in the last quarter. American International Group Inc. boosted its holdings in Zafgen by 36.0% in the third quarter. American International Group Inc. now owns 20,222 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 5,351 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in Zafgen in the third quarter worth approximately $281,000. Hedge funds and other institutional investors own 86.74% of the company’s stock.

Several brokerages have issued reports on ZFGN. Zacks Investment Research lowered Zafgen from a “buy” rating to a “hold” rating in a report on Sunday, January 6th. Svb Leerink upgraded Zafgen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 7th. Cowen restated a “hold” rating on shares of Zafgen in a report on Thursday, January 17th. Piper Jaffray Companies dropped their target price on Zafgen from $18.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, March 11th. Finally, Leerink Swann raised Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 price target for the company in a research report on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Zafgen has a consensus rating of “Hold” and a consensus target price of $9.45.

NASDAQ:ZFGN opened at $2.73 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.12 and a quick ratio of 9.12. Zafgen Inc has a 1 year low of $2.57 and a 1 year high of $12.35. The firm has a market capitalization of $104.47 million, a price-to-earnings ratio of -1.44 and a beta of -0.42.

Zafgen (NASDAQ:ZFGN) last released its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04. On average, equities research analysts predict that Zafgen Inc will post -1.6 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/16/prudential-financial-inc-purchases-new-holdings-in-zafgen-inc-zfgn.html.

About Zafgen

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Featured Story: Float

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.